Skip to content
Clinical Trials – home
Agomab Spain S.L.
Sponsor

Agomab Spain S.L.

Spain Poligono Parque Empresarial Parcelas 26-27, Fonte Diaz, 15822, Spain

About the sponsor

Agomab Spain S.L.U. demonstrates a concentrated focus on addressing fibrotic complications within the gastrointestinal tract, particularly in patients with established inflammatory bowel conditions. The sponsor's research portfolio centers on therapeutic interventions targeting intestinal fibrosis and stricture formation, conditions that represent significant clinical challenges in chronic gastrointestinal disease management.

  • Crohn's Disease Strictures
  • Intestinal Fibrosis Mechanisms
  • Fibrostenotic Complications

The therapeutic development program emphasizes novel approaches to managing stricturing phenotypes in inflammatory bowel disease, exploring mechanisms that may prevent or reverse pathological tissue remodeling in the intestinal wall.

About Specializations

Agomab Spain S.L. runs clinical trials in conditions such as Crohn's disease, Idiopathic pulmonary fibrosis, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

5 clinical trials

Crohn's disease

Recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.

Phase 2 Study of Inhaled AGMB-447 and Salbutamol Sulfate in Adults with Idiopathic Pulmonary Fibrosis to Evaluate Lung Function, Safety and Tolerability

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Agomab Spain S.L.

Crohn's disease

Not recruiting

Relative Bioavailability of AGMB-129 Tablet vs ORG-129 Capsule and Food Effect in Healthy Participants for Fibrostenotic Crohn’s Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.

Crohn's disease

Not recruiting

A study of the effects of AGMB-129 and midazolam in healthy participants

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Midazolam
  • Sponsor:Agomab Spain S.L.

Crohn's disease

Not recruiting

Study on the Safety and Effects of ORG-129 in Patients with Fibrostenotic Crohn's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.